Table 3.
Characteristics | 5-years OS rate | 5-year RFS rate | ||
---|---|---|---|---|
HR (95 % CI) | P Value | HR (95 % CI) | P Value | |
T Stage | ||||
T1 or T2 | 0.547 (0.331–0.904) | 0.019* | 1.188 (0.483–2.923) | 0.707 |
T3 or T4 | Reference | Reference | ||
N Stage | ||||
N0 | 0.238 (0.143–0.398) | 0.000*** | 0.614 (0.280–1.347) | 0.223 |
N1-N3 | Reference | Reference | ||
Clinical Stage | ||||
I-II | 2.503 (1.348–4.649) | 0.004** | 2.249 (0.865–5.852) | 0.097 |
III-IV | Reference | Reference | ||
Foxp3 Staining Value | ||||
1 | 0.197 (0.123–0.315) | 0.000*** | 0.451 (0.239–0.849) | 0.014* |
2 | 0.271 (0.174–0.422) | 0.000*** | 0.371 (0.192–0.714) | 0.003** |
3 | Reference | Reference |
Abbreviations: OS overall survival, RFS, relapse free survival, HR hazard ratio, 95 % CI 95 % confidence interval
P value was determined using Cox proportional-hazards model. *,P<0.05;**, P<0.01;***, P<0.001